Skip to content

Clinical trial-Efficacy and safety of TAZ/PIPC in elderly respiratory tract infection-NHCAP-

Clinical trial-Efficacy and safety of TAZ/PIPC in elderly respiratory tract infection-NHCAP- - Clinical trial-Efficacy and safety of TAZ/PIPC in elderly respiratory tract infection-NHCAP-

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000006034
Enrollment
20
Registered
2011-07-27
Start date
2010-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elderly respiratory tract infection

Interventions

None listed

Sponsors

Shimane University Faculty of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1 elderly people over 65 years old 2 the case fulfilling any of under the points -examined in long-term health facilities for recuperation, the treatment -discharged within 180 days -elderly or handicapped need care -who have received endovascular treatment continued at the hospital (dialysis, antibiotics, anticancer, immunosuppressant therapy, etc.) 3 the case fulfilling all under points two days before from starting of administration -a body temperature higher than 37 degrees C -CRP higher than 1.0mg per dl -evidence of pneumonia in the chest radiography or chest CT

Exclusion criteria

Exclusion criteria: 1 under severe heart damage under severe liver damage under severe kidney damage 2 who is strongly suspected of atypical pneumonia 3 who must be used with non-macrolide antibiotics 4 beta lactam agent allergy 5 who evaluated as inappropriate by doctor in attendance

Design outcomes

Primary

MeasureTime frame
1)Clinical effect of three days later from starting of administration 2)Body temperature,amount of sputum, property of sputum,WBC,ESR,CRP of three days later from starting of administration 3)Total clinical effect of the analysis objects 4)Bacteriological effect of the analysis objects 5)The incidence of the side effects 6)Pharmacological assessment

Countries

Japan

Contacts

Public ContactFumiKARINO

Shimane University Faculty of Medicine Oncology and Respiratory Medicine

fumi1224@med.shimane-u.ac.jp0853-20-2580

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026